Technical Analysis for CLRB - Cellectar Biosciences, Inc.

Grade Last Price % Change Price Change
grade F 2.02 1.51% 0.03
CLRB closed up 1.51 percent on Friday, January 18, 2019, on 4.43 times normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical CLRB trend table...

Date Alert Name Type % Chg
Jan 18 50 DMA Resistance Bearish 0.00%
Jan 18 Stochastic Sell Signal Bearish 0.00%
Jan 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jan 18 Pocket Pivot Bullish Swing Setup 0.00%
Jan 18 Volume Surge Other 0.00%
Jan 18 Wide Range Bar Range Expansion 0.00%
Jan 18 Weak + Overbought Other 0.00%
Jan 18 Outside Day Range Expansion 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%

Older signals for CLRB ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Cellectar Biosciences, Inc., a development stage biopharmaceutical company, develops compounds for the treatment and imaging of cancer. Its proprietary product candidates include I-124-CLR1404, a small-molecule, broad-spectrum, and cancer-targeting positron emission tomography (PET) imaging agent that is in Phase II clinical trial for glioblastoma, as well as in Phase I/II clinical trials for approximately 11 solid tumor indications; and CLR1502, a preclinical, cancer-targeted, and non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. The company also develops I-131-CLR1404, a small-molecule, broad-spectrum, and cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells, as well as is in Phase Ib dose-escalation trial for patients with advanced solid tumors; and CLR1404, a cancer-targeted chemotherapy. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.
Is CLRB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 14.0
52 Week Low 1.22
Average Volume 61,605
200-Day Moving Average 5.2116
50-Day Moving Average 2.0578
20-Day Moving Average 1.707
10-Day Moving Average 1.879
Average True Range 0.2331
ADX 14.64
+DI 30.0313
-DI 15.7101
Chandelier Exit (Long, 3 ATRs ) 1.7307
Chandelier Exit (Short, 3 ATRs ) 1.9193
Upper Bollinger Band 2.1151
Lower Bollinger Band 1.2989
Percent B (%b) 0.88
BandWidth 47.81488
MACD Line -0.0216
MACD Signal Line -0.0818
MACD Histogram 0.0602
Fundamentals Value
Market Cap 28.12 Million
Num Shares 13.9 Million
EPS -1.13
Price-to-Earnings (P/E) Ratio -1.79
Price-to-Sales 0.00
Price-to-Book 1.98
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.10
Resistance 3 (R3) 3.12 2.77 2.92
Resistance 2 (R2) 2.77 2.50 2.77 2.86
Resistance 1 (R1) 2.40 2.33 2.23 2.38 2.80
Pivot Point 2.05 2.05 1.97 2.05 2.05
Support 1 (S1) 1.68 1.78 1.51 1.66 1.24
Support 2 (S2) 1.33 1.61 1.33 1.18
Support 3 (S3) 0.96 1.33 1.12
Support 4 (S4) 0.94